

Attorney Docket No. 46963-DIV (71417)  
U.S.S.N. 09/228,020  
Filing date: January 11, 1999  
Supplemental Amendment and Remarks  
2 of 4

At page 47, please amend the abstract as follows:

E2  
Pharmaceutical products are provided comprising EC progenitors for use in methods for regulating angiogenesis, i.e., for enhancing or inhibiting blood vessel formation, in a selected patient and in some preferred embodiments for targeting an angiogenesis modulator to specific locations. For example, the EC progenitors can be used to enhance angiogenesis or to deliver an angiogenesis modulator, c.g., anti- or pro-angiogenic agents, respectively to sites of pathologic or utilitarian angiogenesis. Additionally, in another embodiment, EC progenitors can be used to induce reendothelialization of an injured blood vessel, and thus reduce restenosis by indirectly inhibiting smooth muscle cell proliferation.

In The Claims

Please amend claim 27, as follows.

E3  
6  
27. (Amended) The pharmaceutical product of claim 26<sup>5</sup>, wherein the vector comprises human immunodeficiency virus (HIV) gag and pol genes.

REMARKS

Applicants thank the Examiner for his helpful suggestions regarding amendments to the specification and title to more clearly reflect the elected invention. As requested by the Examiner, Applicants have amended claim 27 to insert the article "the" before the word "vector". In addition, Applicants have inserted the word "virus" after "human immunodeficiency" in claim